Lantern Pharma Inc. Common Stock (LTRN)
FairStock Score: 58/100 — STEADY
Key Financials
| Current Price | $0.63 |
| Market Cap | $8M |
| P/E Ratio | -0.39 |
| ROE | -400.92% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
As a Buffett-and-Graham-style investor, I start with business quality and earnings. Lantern Pharma is a 16-employee oncology developer with no reported revenue in any filed period I can see. That immediately fails Graham's preference for demonstrated earning power and Buffett's test for a durable moat; the value rests almost entirely on clinical pipeline optionality. The company lost $16.0M in FY2023, $20.8M in FY2024, and $17.1M in FY2025, with the loss narrowing somewhat in FY2025. More recent filings show a net loss of $3.3M in fiscal Q1 2026 (quarter ended 2026-03-31) and $7.1M in fiscal Q2 2026 (quarter ended 2026-06-30), so the burn is not stable. Trailing free cash flow was -$14.1M, a -154.9% FCF yield on the $9.1M market cap; that is a heavy spend relative to the equity's size.
In plain English: Lantern Pharma is a small biotech company trying to develop cancer treatments. It has no product sales and has lost money in each of the last several years, so the business looks financially weak today. At $0.71 a share on 2026-10-13, the price is hard to call cheap based on current numbers because there are no profits or revenue to anchor it.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer